Venture Capital

A Toronto meeting signals a new era for Canada-Grenada ties. It's a calculated move into geothermal energy, regional security, and high-value trade.

Allen Control Systems' massive funding for its autonomous Bullfrog weapon reveals a new reality: venture capital is now funding the future of warfare.

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

A new breed of fund offers Main Street a taste of Silicon Valley's private unicorns. But as Powerlaw Corp. opens the door, are investors ready for the risks?

A $90M investment in a homeless shelter is more than charity; it's a blueprint. Sun Life's model signals a shift from philanthropy to strategic impact investing.

As America rebuilds its industrial base, one firm is tearing down silos, offering a single-source solution of capital and real estate to power the economy.

With corporate boards under intense scrutiny, Quinlan Partners' strategic hires of Lisa Silverman and Mark Skertic signal a new era of proactive defense.

A new diagnostic tool, Delve Detect, is using metagenomic sequencing to unmask elusive pathogens in the brain, offering hope where conventional tests fail.

Hivemind Capital and UC Berkeley launch darkmatter lab, a novel model to inject capital and resources into frontier research before it becomes a company.

Fairplay's new user verification signals a market-wide shift. As India's stringent new rules take hold, compliance is becoming a key strategic asset.

AM Best affirms Fairfax's 'Excellent' rating after a year of record profits and major catastrophes. We deconstruct the strategy behind this financial paradox.

With the hire of veteran Dr. Jesko Kornemann, advisory firm Cork Gully makes a strategic push into Frankfurt, betting on a growing need for special situations expertise.

MIT's Kristin Forbes argues rigid models are failing. She's adapting Sun Tzu's 'Art of War' to help central banks fight today's lightning-fast crises.

Consuelo Vanderbilt Costin's recurring role at the elite Forbes Iconoclast Summit is no social engagement. It's a masterclass in converting legacy into currency.

A recent FDA approval for a generic cancer drug adds to a growing market, revealing the strategic alliances redefining healthcare access.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

Bluejay Diagnostics secures critical funding to advance its rapid sepsis test, extending its cash runway but raising questions about shareholder dilution.

A small startup just raised $4M to solve the biggest problem in tech: making AR glasses affordable. Their secret isn't a new gadget, but a materials science breakthrough.

As AI and cyber risks escalate, the new 'Chief Trust Officer' role is emerging. HITRUST's appointment of a veteran leader signals a major shift for all.

QuadReal's appointment of Deloitte veteran Trevor Nakka signals a strategic pivot, adding elite financial governance to its $98.5B portfolio to fuel a disciplined global expansion.